If the the angiotensin-II/aldosterone-dependent mechanism—causing massive renal potassium loss—is operative in human pathology, this implies that severe hypokalemia by SARS-CoV-2 infection may be amenable to treatment with potassium-sparing drugs antagonizing the aldosterone receptor, such as spironolactone or eplerenone, whereas potassium supplementation (whether oral or IV) even in very high doses may be futile. The gene discussed is NR3C2; the disease is Hypokalemia.